Ipca receives US FDA nod for nausea drug
Drug maker Ipca Laboratories today said it has received US regulatory approval for marketing metoclopramide tablets used in the treatment of nausea.
By PTI |
MUMBAI: Drug maker Ipca Laboratories today said it has received US regulatory approval for marketing metoclopramide tablets used in the treatment of nausea.
"Ipca has received US Food and Drug Administration approval to manufacture and market metoclopramide tablets in 5 mg and 10 mg variants in the US, Lupin said in a filing to the Bombay Stock Exchange.
Ipca had earlier announced a strategic tie-up with US-based Ranbaxy Pharmaceuticals Inc, a wholly-owned subsidiary of domestic pharma major Ranbaxy Laboratories Ltd.
Metoclopramide tablets are also used in the treatment of nausea related to postoperative state and cancer chemotherapy.
Ipca would manufacture and Ranbaxy would market the drug in the US. "Ranbaxy will commercialise this product in the US market utilising its established marketing expertise and distribution network," the filing added.
This is the sixth such product approval received under the alliance from US FDA, it said.
Shares of Lupin were trading at Rs 577.05, up 1.02 per cent, in the afternoon trade on the BSE.
"Ipca has received US Food and Drug Administration approval to manufacture and market metoclopramide tablets in 5 mg and 10 mg variants in the US, Lupin said in a filing to the Bombay Stock Exchange.
Ipca had earlier announced a strategic tie-up with US-based Ranbaxy Pharmaceuticals Inc, a wholly-owned subsidiary of domestic pharma major Ranbaxy Laboratories Ltd.
Metoclopramide tablets are also used in the treatment of nausea related to postoperative state and cancer chemotherapy.
Ipca would manufacture and Ranbaxy would market the drug in the US. "Ranbaxy will commercialise this product in the US market utilising its established marketing expertise and distribution network," the filing added.
This is the sixth such product approval received under the alliance from US FDA, it said.
ADVERTISEMENT
Shares of Lupin were trading at Rs 577.05, up 1.02 per cent, in the afternoon trade on the BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
